News

February 20, 2012 —Medtronic announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity drug-eluting stent (DES)...

February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus Element Plus everolimus-eluting coronary stent system. The first patient implant in...

January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the asserted patents for a coronary stent in a lawsuit brought by Johnson...

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower...

Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (...

Boston Scientific recently announced U.S. Food and Drug Administration (FDA) approval for the Promus Element Plus everolimus-eluting platinum chromium coronary stent system, the company's next-...

December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial evaluating the safety, efficacy and performance of the...

November 21, 2011 — Micell Technologies Inc. announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent...

November 15, 2011 – The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain...

November 15, 2011 – A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting...

November 15, 2011 — Results of ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT)...

November 15, 2011 — Researchers have found polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared...

November 15, 2011 — A new clinical trial is testing the efficacy of rotational atherectomy (or rotablation, a process of drilling through plaque deposits) prior to implantation of a drug-eluting...

November 15, 2011 — A clinical trial has shown a drug-eluting stent (DES) with a bioabsorbable polymer has comparable outcomes to a DES with a durable polymer. Results of the EVOLVE clinical trial...

November 14, 2011 – OrbusNeich announced the introduction of the Combo dual therapy stent during a breakfast symposium chaired by Martin B. Leon, M.D., professor of medicine and director of the...

November 14, 2011 – The TWENTE clinical trial, which compared Resolute versus Xience V drug-eluting stents in a real-world population established non-inferiority between the two stents as measured...

November 11, 2011 – Boston Scientific reported results from the EVOLVE first human use trial demonstrating the non-inferiority of the Synergy everolimus-eluting stent system compared to the Promus...

November 11, 2011 – Biosensors International Group announced two-year results from the BioFreedom first-in-human trial, which showed similar clinical outcomes between BioFreedom, a polymer-free,...

November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting stent (DES) from Medtronic Inc. continues to demonstrate consistently positive...

November 8, 2011 — Biosensors International Group Ltd. announced final results of the AXXESS PLUS trial, which demonstrated the long-term efficacy and safety of the Axxess stent for patients with...